Publication Name	World Journal of Hepatology
Manuscript ID	110080
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Non-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease
Manuscript Source	Invited Manuscript
All Author List	Yan-Hua Zhao, Shu-Sheng Leng, Yan Wang, Fa-Zhi Kui and Wei Gan
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China No. 82402719 Sichuan Science and Technology Program No. 2025ZNSFSC1553
Corresponding Author	Wei Gan, PhD, Professor, Department of Laboratory Medicine, West China Hospital, Sichuan University, Sichuan Clinical Research Center for Laboratory Medicine, and Clinical Laboratory Medicine Research Center of West China Hospital, No. 37 Guoxue Lane, Wuhou District, Chengdu 610041, Sichuan Province, China. 2004ganwei@scu.edu.cn
Key Words	Metabolic dysfunction-associated steatotic liver disease; Non-invasive test; Blood biomarkers; Liver fibrosis; Patented panel
Core Tip	Current biomarkers (fibrosis-4, non-alcoholic fatty liver disease fibrosis score) provide accessible first-line screening for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis but require age/obesity-adjusted thresholds. Patented panels (enhanced liver fibrosis, FibroMeter) enhance precision through metabolic/extracellular matrix markers yet need MASLD-specific validation. Emerging biomarkers (propeptide of type 3 collagen, Mac-2 binding protein glycosylation isomer, epigenetic regulators like proliferator-activated receptor-γ methylation, angiopoietin-like proteins such as angiopoietin-like protein a family of eight glycoproteins) show monitoring potential but need validation. No single biomarker replaces biopsy. Combining existing tools with novel multi-omics approaches and MASLD-specific diagnostic frameworks is critical for improving clinical outcomes in this epidemic.
Citation	Zhao YH, Leng SS, Wang Y, Kui FZ, Gan W. Non-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease. World J Hepatol 2025; In press

Received	2025-05-29 06:19
Peer-Review Started	2025-06-06 09:02
To Make the First Decision
Return for Revision	2025-06-17 09:20
Revised	2025-07-01 08:17
Second Decision	2025-10-09 02:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-10-10 08:00
Articles in Press	2025-10-10 08:00
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com